source
- Biotech M&A slows sharply in Q3 as deal activity coolsThe third quarter saw a noticeable slowdown in biotech mergers and acquisitions after a busy first half of the year. Large upfront licensing agreements were fewer, and venture capital firms reduce…
- Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engagerRoche will pay Zymeworks $55 million upfront plus another $40 million once the partnership asset enters Phase 1b development and up to $718 million in additional milestones.